Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].

Psychiatria polska - 1 Jan 2000

Zabrocka M, Woszczek G, Borowiec M, Rabe-Jabłońska J, Kowalski M L

Abstract excerpt

The debrisoquine polymorphism is a genetic variation in oxidative drug metabolism mediated by CYP2D6 gene, characterized by two phenotypes, the extensive metabolizer (EM) and poor metabolizer (PM). PM phenotype is inherited as autosomal recessive trait and occurs in 5-10% of Caucasian population. It is associated with the inefficient metabolism of over 30 drugs, including many psychotropic drugs. Clinical studies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Resistance

Share to Gene Expression

Share to Mental Disorders

Share to Point Mutation

Share to Psychotropic Drugs

Source

Identifiers

PMID: 10786218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].PMID 10786218Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

[Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese].Semantic proximity Read ↗

[Genetic polymorphism in human drug metabolism].Semantic proximity Read ↗

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.Semantic proximity Read ↗

Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implicationSemantic proximity Read ↗

[Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].Semantic proximity Read ↗

[Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].Semantic proximity Read ↗

Identification of CYP2D6 allelic mutations in a sub-set of Karachi populationSemantic proximity Read ↗

Identification of CYP2D6 allelic mutations in a sub-set of Karachi populationSemantic proximity Read ↗

CYP2D6 genotyping in patients on psychoactive drug therapy.Semantic proximity Read ↗

[The relevance of genetically determined polymorphism CYP2D6 in psychopharmacology; the relationship between genotype and phenotype].Semantic proximity Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.